125 related articles for article (PubMed ID: 20683040)
1. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer.
Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A
Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040
[TBL] [Abstract][Full Text] [Related]
2. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
Polyzos A; Kalbakis K; Kentepozidis N; Giassas S; Kalykaki A; Vardakis N; Bozionelou V; Saloustros E; Kontopodis E; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2011 Jul; 68(1):217-23. PubMed ID: 20922389
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
[TBL] [Abstract][Full Text] [Related]
5. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
[TBL] [Abstract][Full Text] [Related]
6. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
7. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
10. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
[TBL] [Abstract][Full Text] [Related]
11. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
Sikov WM; Dizon DS; Strenger R; Legare RD; Theall KP; Graves TA; Gass JS; Kennedy TA; Fenton MA
J Clin Oncol; 2009 Oct; 27(28):4693-700. PubMed ID: 19720916
[TBL] [Abstract][Full Text] [Related]
12. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
[TBL] [Abstract][Full Text] [Related]
13. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.
Modi S; D'Andrea G; Norton L; Yao TJ; Caravelli J; Rosen PP; Hudis C; Seidman AD
Clin Breast Cancer; 2006 Aug; 7(3):270-7. PubMed ID: 16942645
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
Seidman AD; Berry D; Cirrincione C; Harris L; Muss H; Marcom PK; Gipson G; Burstein H; Lake D; Shapiro CL; Ungaro P; Norton L; Winer E; Hudis C
J Clin Oncol; 2008 Apr; 26(10):1642-9. PubMed ID: 18375893
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
